Azathioprine

Generic Name: Azathioprine

Brand Names: Azasan, Imuran, Jayempi

Drug Type: Small Molecule

Chemical Formula: C_₉H_₇N_₇O_₂S

CAS Number: 446-86-6

Unique Ingredient Identifier: MRK240IY2L

Background: Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index. Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transp...

Indication: Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.

Associated Conditions: Atopic Dermatitis, Crohn's Disease (CD), Immune Thrombocytopenia (ITP), Kidney Transplant Rejection, Lupus Nephritis, Multiple Sclerosis, Pericarditis, Psoriasis, Rheumatoid Arthritis, Uveitis

Associated Therapies: -

Clinical Trials

MMF vs. AZA for Kidney Transplantation

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: mycophenolate mofetil
Drug: azathioprine

First Posted Date: 2007-07-02

Last Posted Date: 2017-12-13

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 233

Registration Number: NCT00494741

Locations: 🇮🇹
Hospital "Niguarda Cà Granda", Milano, Italy
🇮🇹
Hospital "Spedali Civili" - Unit of Nephrology and Dialysis, Brescia, Italy
🇮🇹
Policlinico Gemelli, Roma, Italy

and more 3 locations

A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate Mofetil
Drug: Corticosteroids
Drug: Azathioprine
Drug: Cyclophosphamide

First Posted Date: 2007-01-23

Last Posted Date: 2014-09-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT00425438

CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors

Phase 4

Conditions: Polyarteritis Nodosa
Microscopic Polyangiitis

First Posted Date: 2006-11-16

Last Posted Date: 2006-11-16

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 124

Registration Number: NCT00400075

Locations: 🇨🇭
Camillo Ribi, Geneva, Switzerland

CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors

Phase 4

Conditions: Churg-Strauss Syndrome

First Posted Date: 2006-11-14

Last Posted Date: 2006-11-14

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 72

Registration Number: NCT00399399

Locations: 🇨🇭
Camillo Ribi, Geneva, Switzerland

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide
Drug: Azathioprine
Drug: Corticosteroid
Drug: Placebo to Azathioprine
Drug: Placebo to Mycophenolate mofetil

First Posted Date: 2006-09-18

Last Posted Date: 2011-12-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 370

Registration Number: NCT00377637

Comparison of Sirolimus and Azathioprine in Lung Transplantation

Phase 4

Completed

Conditions: Delayed Graft Function
Acute Graft Rejection

Interventions: Drug: azathioprine
Drug: sirolimus

First Posted Date: 2006-05-04

Last Posted Date: 2016-09-21

Lead Sponsor: University of Chicago

Target Recruit Count: 181

Registration Number: NCT00321906

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

Phase 3

Terminated

Conditions: ANCA Associated Systemic Vasculitis Including Wegener's
Granulomatosis and Microscopic Polyangiitis and
Renal Limited Vasculitis

First Posted Date: 2006-03-28

Last Posted Date: 2006-04-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 160

Registration Number: NCT00307645

Locations: 🇬🇧
Addenbrooke's Hospital - Departement of Medecine, Cambridge, United Kingdom
🇫🇷
Hopital Cochin, Paris, France

Aerosol Cyclosporine for Prevention of Lung Rejection

Phase 2

Completed

Conditions: Lung Diseases

First Posted Date: 2005-12-22

Last Posted Date: 2016-05-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00268515

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Phase 2

Withdrawn

Conditions: Systemic Lupus Erythematosus

Interventions: Procedure: Plasmapheresis
Procedure: Leukapheresis
Drug: Rabbit anti-thymocyte globulin
Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
Procedure: Autologous CD34+HPC transplantation (HSCT)
Drug: Methylprednisolone
Drug: Growth colony stimulating factor (G-CSF)
Drug: Corticosteroids
Drug: Mycophenolate mofetil
Drug: Azathioprine
Drug: Intravenous immunoglobulin
Drug: Methotrexate
Drug: Rituximab
Drug: Leflunomide

First Posted Date: 2005-09-30

Last Posted Date: 2013-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00230035

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
UCSD, Thornton Hospital, La Jolla, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil
Drug: Azathioprine

First Posted Date: 2005-09-20

Last Posted Date: 2011-10-14

Lead Sponsor: Frédéric A. Houssiau, MD, PhD

Target Recruit Count: 105

Registration Number: NCT00204022

Locations: 🇧🇪
Université catholique de Louvain, Bruxelles, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy